Provided By GlobeNewswire
Last update: May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds.
Read more at globenewswire.com2.34
-0.1 (-4.1%)
Find more stocks in the Stock Screener